Ultragenyx Pharmaceutical (RARE) Change in Intangibles (2018)
Ultragenyx Pharmaceutical's (RARE) quarterly Change in Intangibles came in at $80.6 million in Q2 2018, down 38.0% on a QoQ basis from $130.0 million in Q1 2018.
Ultragenyx Pharmaceutical (RARE) Change in Intangibles (2018) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 1 years of Change in Intangibles data on file, last reported at $80.6 million in Q2 2018.
- On a quarterly basis, Change in Intangibles changed N/A year-over-year to $80.6 million in Q2 2018; TTM through Dec 2018 was $210.6 million, a N/A change from a year earlier, with the FY2019 full-year figure at $314.2 million, up 84.49% from the prior year.
- Change in Intangibles for Q2 2018 stood at $80.6 million, down from $130.0 million in the prior quarter.
- Over the last five years, Change in Intangibles for RARE reached as high as $130.0 million in Q1 2018 and fell as low as $80.6 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | - |
| 10 | Ultragenyx Pharmaceutical | 2.73 Bn | 2.32 Bn | 106.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 80.60 Mn |
| Jun 30, 2018 | 80.60 Mn |
| Mar 31, 2018 | 130.00 Mn |
| Mar 31, 2018 | 130.00 Mn |